Mark I. van Berge Henegouwen

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

Pieter van Hagen, Maarten C.C.M. Hulshof, J. Jan B. van Lanschot et al. · New England Journal of Medicine · 2012 · 5.3K citations · Full text

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial

Joël Shapiro, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · The Lancet Oncology · 2015 · 2.5K citations

Surgical Oncology, Neoadjuvant Chemoradiotherapy, Esophageal Cancer +9

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study

Dmitri Nepogodiev, Aneel Bhangu, James Glasbey et al. · The Lancet · 2020 · 1.7K citations · Full text

International Cohort Study, Medicine, Patient Safety +11

Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial

Surya S. A. Y. Biere, Mark I. van Berge Henegouwen, K. W. Maas et al. · The Lancet · 2012 · 1.7K citations

Surgical Oncology, Esophagus, Esophageal Cancer +9

Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial

Ben M. Eyck, J. Jan B. van Lanschot, Maarten C.C.M. Hulshof et al. · Journal of Clinical Oncology · 2021 · 709 citations · Full text